Dominic D'Agostino

Yeah.

Depending on what guy.

But I think maybe the more looser guidelines saying it becomes problematic after five.

We had a review come out with 49 authors and the title was Ketone Metabolic Therapy Framework for Glioblastoma.

So that includes basic science researchers, a number of oncologists at major cancer centers and stuff.

So the gist of that, I think it's really important to focus on cancers where the standard of care doesn't work.

So advanced metastatic cancer, obviously pancreatic and glioblastoma, but glioblastoma has always been sort of the part of what we're studying.

And I think the idea is to make metabolic therapy part of the standard of care.

So the general gist with that review and the senior author of Dr. Thomas Seyfried, and I know you've had him on the podcast, Tomas Durak, he was the primary author.

In that review, it creates a framework.

There's so much in that review.

It ended up, it was like 200 pages carved down to like 50 pages with about a thousand references, making it super concise explanation.

So the gist of that for ketone metabolic therapy for cancer management, specifically glioblastoma, but we think similar reviews can be written for other types of cancers that are specifically, that are highly glycolytic and have the Warburg effect.

So really hot on an FGG PET scan.

So above 2.5 SUVs, like on a PET scan would define it as hyperglycolytic.

Achieve and maintain a glucose ketone index of 1 to 4.

So that's the millimolar concentration of glucose over ketones.

So if your glucose was 4, which is relatively normal, and your ketone levels were 1, you

Where I'm at now.

So that gives me a GKI of four.